Redeye reviews its financial estimates on all time horizons following Episurf Medical's most recent strategy update and its progression in the US market with its Patellofemoral system. We emphasise its quick commercial focus shift and highlight that its anticipated accelerating US progress put Episurf in an entirely new light. Our financial estimates revision (also factoring in an equity issue) renders a lowered fair value range.